Evaluating a psychological intervention for ovarian cancer patients
Official title: A Feasibility Trial of Managing Cancer and Living Meaningfully (CALM) in Patients With Newly Diagnosed and Recurrent Advanced Ovarian Cancer
Run by University Health Network, Toronto · NCT06459271 · Data updated 2026-11-12
This study is testing a new therapy called CALM to see if it helps people who have just been diagnosed or have had a recurrence of advanced ovarian cancer feel better and cope with their situation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | June 10, 2024 |
| Main results expected | February 2027 |
| Study ends | June 2027 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT06459271 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with a new diagnosis or recurrence of stage III or IV ovarian cancer.
✕Probably not a fit
Patients with cognitive impairments or those currently receiving psychological counseling may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This feasibility trial aims to assess the implementation and acceptability of the Managing Cancer And Living Meaningfully (CALM) intervention for patients newly diagnosed or recently recurred with advanced ovarian cancer. Participants will complete questionnaires at baseline, 3 months, and 6 months, and may engage in 3-6 sessions of CALM therapy. The study will also explore the prevalence of traumatic stress symptoms in these patients and gather insights from those who opt out of the intervention. The findings could pave the way for a larger randomized effectiveness trial.
Why it matters
Potential benefit: If successful, this intervention could significantly improve psychological well-being and reduce traumatic stress symptoms in ovarian cancer patients.
How similar studies have gone: While CALM has shown effectiveness in later stages of cancer care, its application shortly after diagnosis in ovarian cancer is novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * new diagnosis or recurrence of stage III or stage IV OC; * age ≥18 years * able to complete outcome measures and engage in CALM in English. Exclusion Criteria: * evidence of cognitive impairment indicated in the medical record, communicated by the OC clinic team, or determined by research staff at recruitment; * receiving psychological or psychiatric counseling from the Department of Supportive Care at PM at the time of recruitment.
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Gary M Rodin, MD — University Health Network, Toronto
- Study coordinator: Megan A George, BSc
- Email: megan.george@uhn.ca
- Phone: 6475463114
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How a patient experience check-in helps people in intermediate and long-term care feel more trusted in the hospital
This study tests whether identifying and acting on patient concerns in intermediate and long-term care units can help older patients trust the hospital more and reduce complaints.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.